Abpro Holdings Files 8-K
Ticker: ABPWW · Form: 8-K · Filed: Dec 15, 2025 · CIK: 1893219
Sentiment: neutral
Topics: sec-filing, 8-k, reporting
Related Tickers: ABP
TL;DR
Abpro Holdings filed a routine 8-K on 12/15/25. No major news.
AI Summary
Abpro Holdings, Inc. filed an 8-K on December 15, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly Atlantic Coastal Acquisition Corp. II, is incorporated in Delaware and has its principal executive offices in Burlington, MA. This filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This 8-K filing indicates Abpro Holdings, Inc. is meeting its reporting obligations with the SEC, which is standard for publicly traded companies.
Risk Assessment
Risk Level: low — This filing is a routine 8-K and does not disclose any new material risks or events.
Key Players & Entities
- Abpro Holdings, Inc. (company) — Registrant
- Atlantic Coastal Acquisition Corp. II (company) — Former company name
- December 15, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Burlington, MA (location) — Principal executive office location
FAQ
What is the primary purpose of this 8-K filing for Abpro Holdings, Inc.?
The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits.
When was this 8-K report filed?
This 8-K report was filed on December 15, 2025.
What was Abpro Holdings, Inc.'s former name?
Abpro Holdings, Inc.'s former name was Atlantic Coastal Acquisition Corp. II.
In which state is Abpro Holdings, Inc. incorporated?
Abpro Holdings, Inc. is incorporated in Delaware.
Where are Abpro Holdings, Inc.'s principal executive offices located?
Abpro Holdings, Inc.'s principal executive offices are located in Burlington, MA.
Filing Stats: 557 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2025-12-15 07:16:26
Key Financial Figures
- $0.0001 — red Shares of Common Stock, par value $0.0001 per share ABP The Nasdaq Stock Mark
- $114.90 — of Common Stock at an exercise price of $114.90 ABPWW The Nasdaq Stock Market LLC
Filing Documents
- ea0269613-8k_abpro.htm (8-K) — 28KB
- ea026961301ex99-1_abpro.htm (EX-99.1) — 16KB
- ex99-1_001.jpg (GRAPHIC) — 2KB
- 0001213900-25-121446.txt ( ) — 259KB
- abp-20251215.xsd (EX-101.SCH) — 4KB
- abp-20251215_def.xml (EX-101.DEF) — 26KB
- abp-20251215_lab.xml (EX-101.LAB) — 36KB
- abp-20251215_pre.xml (EX-101.PRE) — 25KB
- ea0269613-8k_abpro_htm.xml (XML) — 6KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On December 15, 2025, Abpro Holdings, Inc. (the "Company") issued a press release announcing that the Company submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a phase 1 clinical trial of T cell engager ABP-102/CT-P72 for HER2-positive cancers. A copy of the press release is attached hereto as Exhibit 99.1 hereto and is incorporated into this Item 7.01 by reference. The information in this Item 7.01 of this Current Report on Form 8-K, including the exhibit, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release, dated December 15, 2025 104 Cover Page Interactive Data File (embedded within the inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABPRO HOLDINGS, INC. By: /s/ Miles Suk Name: Miles Suk Title: Chief Executive Officer Dated: December 15, 2025 2